Participants achieving HBsAg loss with pegylated interferon alfa (PEG-IFNα) ± elebsiran or BRII-179 demonstrated favorable off-treatment clinical outcomes, with most HBsAg rebounds ‑treatment ...
A panelist discusses how the COAT trial showed that switching patients with uncontrolled dry eye disease on cyclosporine 0.05% to the 0.09% solution led to significant improvements in corneal staining ...
Multicentric Validation of a Complete Blood Count–Based Model for Breast Cancer Risk Stratification in Women Age 40-49 Years A variety of retrospective and prospective data collected through the CCDI ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results